India's Aurobindo Pharma gains on US FDA nod for anti-cancer tablet Dasatinib

Shares of drug maker Aurobindo Pharma ARBN.NS rise as much as 4.2% to 1,237.70 rupees

Unit receives U.S. FDA's approval for Dasatinib tablets

Adds, Dasatinib, used as anti-cancer medication, is expected to be launched in Q1FY26

Stock top gainer in Nifty Pharma Index .NIPHARM which is up 1.1%

Share price above 50-day, 100-day and 200-day exponential moving averages

Avg rating of 25 analysts equivalent of "buy", median PT is 1,463 rupees - data compiled by LSEG

Stock last up 4.1%, cutting YTD loss to 7.3%